Niphatenones a Completely New Class of Androgen Receptor Antagonist

Marianne Sadar, PhD
Senior Scientist, Michael Smith Genome Sciences Centre, BC Cancer Agency
Honorary Associate Professor, Department of Pathology and Laboratory Medicine
University of British Columbia

Dr. Sadar has discovered and is developing compounds derived from undersea plant life for development of new treatments for metastatic prostate cancer. Some of these compounds block the activation of the androgen receptor and possess antitumor activity. These compounds, called niphatenones, will be thoroughly investigated as clinical therapeutic candidates for treatment of metastatic prostate cancer.

Potential patient benefit: Niphatenones represent a new class of antineoplastic medication for treatment of metastatic prostate cancer.